NEW YORK, July 30, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Altimmune, Inc. (NASDAQ: ALT) on behalf of long-term stockholders following a class action complaint that was filed against Altimmune on May 6, 2024 with a Class Period from December 1, 2023 to April 26, 2024. Our investigation concerns whether the board of directors of Altimmune have breached their fiduciary duties to the company. Altimmune ...

Weekly subcutaneous doses of pemvidutide resulted in up to 68.5% relative reduction in liver fat content (LFC), with up to 55.6% of subjects achieving LFC normalization after 12 weeks of treatment LFC changes were accompanied by significant improvements in body weight and non-invasive markers of liver inflammation Pemvidutide is currently being evaluated in the Phase 2b IMPACT trial in subjects with metabolic dysfunction-associated steatohepatitis (MASH), with data readout expected in Q1 2025 GAITHERSBURG, ...

Weekly subcutaneous doses of pemvidutide resulted in up to 68.5% relative reduction in liver fat content (LFC), with up to 55.6% of subjects achieving LFC normalization after 12 weeks of treatment LFC changes were accompanied by significant improvements in body weight and non-invasive markers of liver inflammation Pemvidutide is currently being evaluated in the Phase 2b IMPACT trial in subjects with metabolic dysfunction-associated steatohepatitis (MASH), with data readout expected in Q1 2025 GAITHERSBURG, ...

At least one of the pair has a credible shot at finding a home in the market.Eli Lilly and Novo Nordisk are, for now, the undisputed champions of the market for weight-loss medicines. Thanks to the outrageous popularity of Lilly's drug Zepbound and Novo's product Wegovy, the biggest contest of the moment will go to whoever can ramp up their manufacturing capacity the fastest, such that they can serve the market's overflowing demand.But the market for weight-loss therapies could be as large as $100 billion b ...

文章核心观点 - 生物技术行业正在快速发展,基因编辑技术日趋成熟,人工智能在药物发现中的作用也日益重要 [2] - 生物技术行业具有高度波动性,临床试验和FDA批准是决定公司命运的关键因素 [3] - 选择合适的生物技术股票可能带来爆发性收益,文中提到的几只股票都有至少80%的上涨空间 [4] 公司和行业总结 Viking Therapeutics (VKTX) - 公司的重点产品VK2735在减重领域表现出色,临床试验数据显示其可能是一款潜力巨大的减重药物 [6][7] - 根据高盛预测,到2030年全球减重市场规模可能达到1300亿美元,为公司带来巨大的增长空间 [6] - 有消息称可能会有大型制药公司收购该公司,这可能成为VKTX股票的重大催化剂 [7] - 10家华尔街分析师给予该股"强烈买入"评级,预测其有89%的上涨空间 [7] Altimmune (ALT) - 公司的减重候选药物pemvidutide在临床试验中显示出良好的疗效,能够在减重的同时保持肌肉量 [10] - 该药物还显示出治疗脂肪肝和乙型肝炎的潜力,FDA已经给予其治疗某种脂肪肝疾病的快速通道 [11] - 5家华尔街分析师给予该股"强烈买入"评级,预测其有171%的上涨空间 [11] Zura Bio (ZURA) - 公司拥有3款候选药物即将进入II期临床试验,主要针对免疫和炎症性疾病 [13][14] - 其中最重要的是治疗慢性炎症性皮肤病和系统性硬化症的药物 [14] - 华尔街共识预测该股有478%的上涨空间 [15]

Tired of watching your portfolio crawl along? Standard investment advice often includes diversifying into bland, safe bets. But what if you desire higher returns, even if it means more risk? Strategic investment in well-researched, riskier wild-card stocks can be the secret ingredient to amplifying your gains. Yes, there’s a chance of getting burned, but with careful selection and a dash of courage, you could just as easily win. So, ditch the boring and consider embracing the bold. Not all investors have th ...

NEW YORK, July 02, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Altimmune investors who were adversely affected by alleged securities fraud between December 1, 2023 and April 26, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/altimmune-inc-lawsuit-sub ...

GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will be hosting one-on-one meetings with institutional investors at the Leerink Partners Therapeutics Forum: I&I and Metabolism, being held on July 9 and 10, 2024 in Boston, MA. The event will feature analyst-hosted panel discussions with leading physicians in a range of autoimmune and metabolic indications, as well as me ...

NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Altimmune, Inc. (NASDAQ: ALT). Shareholders who purchased shares of ALT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/altimmune-inc-loss-submission-form/?id=88044&from=3 CLASS PERIOD: December 1, 2023 t ...

While their share prices have traveled different paths recently, the similarity between the two companies is striking. Altimmune (ALT 4.15%) and Viking Therapeutics (VKTX 4.41%) have a lot of features in common, but, at least for the moment, the performance of their stocks is not one of them. Whereas Viking's shares are up by 610% over the last three years, Altimmune's are down by 54%. However, there's more than one argument for why Altimmune's next act could look a lot more like Viking's trajectory. So let ...